Cdk4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

HIGHLIGHTS

• who: Graziana Digiacomo from the University of Chicago Medicine, United States have published the research work: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells, in the Journal: (JOURNAL)
• what: In this regard, different strategies are currently under evaluation, including approaches exploring the anti-cancer properties of compounds normally used for other medical purposes , or combinatorial approaches aimed at improving the efficacy of the therapies used in the clinical practice . The authors provide evidence that the simultaneous combination of the CDK4/6 inhibitors abemaciclib and ribociclib with lenvatinib is effective in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.